Biomarkers, matrices and analytical methods targeting human exposure to chemicals selected for a European human biomonitoring initiative by Vorkamp, Katrin et al.
Contents lists available at ScienceDirect 
Environment International 
journal homepage: www.elsevier.com/locate/envint 
Biomarkers, matrices and analytical methods targeting human exposure to 
chemicals selected for a European human biomonitoring initiative 
Katrin Vorkampa,⁎, Argelia Castañob, Jean-Philippe Antignacc, Luis D. Boadad, Enrique Cequiere,1,  
Adrian Covacif, Marta Esteban Lópezb, Line S. Hauge, Monika Kasper-Sonnenbergg,  
Holger M. Kochg, Octavio Pérez Luzardod, Agnese Osīteh, Loïc Rambaudi,  
Maria-Teresa Pinorinij,2, Gabriele Sabbionij,2, Cathrine Thomsene 
a Aarhus University, Department of Environmental Science, Denmark 
b Instituto de Salud Carlos III, National Centre for Environmental Health, Spain 
c Oniris, INRAE, LABERCA, Nantes, France 
d University of Las Palmas de Gran Canaria, Institute for Biomedical and Health Research, Spain 
e Norwegian Institute of Public Health, Norway 
f University of Antwerp, Toxicological Centre, Belgium 
g Institute for Prevention and Occupational Medicine of the German Social Accident Insurance - Institute of the Ruhr-University, Germany 
h University of Latvia, Department of Analytical Chemistry, Latvia 
i Santé Publique France, Department of Environmental and Occupational Health, France 
j Alpine Institute of Chemistry and Toxicology, Olivone, Switzerland   
A R T I C L E  I N F O   






Per- and polyfluoroalkyl substances 
Phthalates 
A B S T R A C T   
The major purpose of human biomonitoring is the mapping and assessment of human exposure to chemicals. The 
European initiative HBM4EU has prioritized seven substance groups and two metals relevant for human ex-
posure: Phthalates and substitutes (1,2-cyclohexane dicarboxylic acid diisononyl ester, DINCH), bisphenols, per- 
and polyfluoroalkyl substances (PFASs), halogenated and organophosphorous flame retardants (HFRs and 
OPFRs), polycyclic aromatic hydrocarbons (PAHs), arylamines, cadmium and chromium. As a first step towards 
comparable European-wide data, the most suitable biomarkers, human matrices and analytical methods for each 
substance group or metal were selected from the scientific literature, based on a set of selection criteria. The 
biomarkers included parent compounds of PFASs and HFRs in serum, of bisphenols and arylamines in urine, 
metabolites of phthalates, DINCH, OPFRs and PAHs in urine as well as metals in blood and urine, with a pre-
ference to measure Cr in erythrocytes representing Cr (VI) exposure. High performance liquid chromatography- 
tandem mass spectrometry (LC-MS/MS) was the method of choice for bisphenols, PFASs, the HFR hex-
abromocyclododecane (HBCDD), phenolic HFRs as well as the metabolites of phthalates, DINCH, OPFRs and 
PAHs in urine. Gas chromatographic (GC) methods were selected for the remaining compounds, e.g. GC-low 
resolution MS with electron capture negative ionization (ECNI) for HFRs. Both GC–MS and LC-MS/MS were 
suitable for arylamines. New developments towards increased applications of GC–MS/MS may offer alternatives 
to GC–MS or LC-MS/MS approaches, e.g. for bisphenols. The metals were best determined by inductively cou-
pled plasma (ICP)-MS, with the particular challenge of avoiding interferences in the Cd determination in urine. 
The evaluation process revealed research needs towards higher sensitivity and non-invasive sampling as well as a 
need for more stringent quality assurance/quality control applications and assessments.   
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Human biomonitoring studies and programmes aim to generate 
reliable and robust data on the occurrence of a specific biomarker in 
human matrices, such as serum, urine, hair or human milk (WHO, 
2015). Besides their overall objectives of providing data for risk as-
sessments and policy making (Ganzleben et al., 2017; Zidek et al., 
2017), human biomonitoring studies often target the exposure to spe-
cific chemicals, stratified by geography (Den Hond et al., 2015), age 
group (Choi et al., 2017), monitored over time (Koch et al., 2017; Zietz 
et al., 2008) or combinations of these (Schulz et al., 2007; Kolossa- 
Gehring et al., 2012). Biomonitoring data reflect the internal exposure 
(or dose), i.e. the actual uptake, accumulation and/or metabolism of a 
certain chemical, at the same time integrating multiple exposure routes 
(inhalation, ingestion, dermal uptake) and exposure sources, e.g. food, 
consumer products, industrial processes and occupational settings, and 
considering the individual exposure susceptibility. 
With about 150,000 chemical substances pre-registered in the 
European Union (EU) under the EU legislation Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) (Öberg and Iqbal, 
2012), the general population as well as the work force of the EU can be 
exposed to a wide range of different chemicals. Biomonitoring in 
Europe was organised in national programmes or specific studies, with 
little coordination and incomplete geographical coverage before the 
EU-funded projects ESBIO, COPHES and DEMOCOPHES (Joas et al., 
2015; Den Hond et al., 2015). In 2017, an initiative was started under 
the acronym HBM4EU that has brought together scientists from 30 
countries and the European Environment Agency to coordinate and 
advance human biomonitoring in Europe (Ganzleben et al., 2017). 
Large-scale biomonitoring programmes for the general population have 
been in place outside of Europe for several years, including the National 
Health and Nutrition Examination Survey (NHANES) of the United 
States of America, the Canadian Health Measures Survey (CHMS) and 
the Japan Environment and Children’s Study (JECS) (Ganzleben et al., 
2017). 
Based on policy-related research needs, evidence of exposure, con-
cern for human health as well as financial and technical feasibility, the 
following seven substance groups and two metals were selected as the 
first set of prioritised substances in HBM4EU (Table 1): Phthalates (and 
the replacement 1,2-cyclohexane dicarboxylic acid diisononyl ester, 
DINCH), bisphenols, per- and polyfluoroalkyl substances (PFASs), ha-
logenated and organophosphorous flame retardants (HFRs and OPFRs), 
polycyclic aromatic hydrocarbons (PAHs), arylamines, cadmium (Cd) 
and chromium (Cr). A list of acronyms is given in Table S1. 
Several factors have to be considered in the design of a human 
biomonitoring programme or the use of biomonitoring data, for ex-
ample whether the parent compound or a stable metabolite is the most 
suitable biomarker and in which matrix it should be determined. 
Analytical methods have to be sufficiently sensitive and selective to 
produce reliable data. The objective of this study was therefore i) to 
identify the most suitable biomarkers (parent compound vs. metabo-
lites) for the selected substance groups and metals, ii) to describe the 
most suitable human matrix for their biomonitoring and iii) to discuss 
state-of-the-art analytical methods for the determination of this bio-
marker in this matrix. The prioritized biomarker and matrix combina-
tions form the basis for further work in HBM4EU, including the sample 
selection and a comprehensive quality assurance/quality control (QA/ 
QC) programme to ensure precise, accurate and comparable data across 
the EU. 
2. Selected substances and metals 
Phthalates and DINCH are plasticizers ubiquitously detected in the 
indoor environment and food as well as in humans (Wittassek et al., 
2011; Schütze et al., 2017). Exposure to some phthalates has been as-
sociated with adverse effects in laboratory animals and epidemiological 
studies, caused by endocrine disruption (Table 1). Several phthalates 
have been classified as toxic for reproduction in the EU and are 
therefore listed as Substances of Very High Concern (SVHC) under EU 
REACH, triggering specific legislation (EU, 2006). Di(2-ethylhexyl) 
phthalate (DEHP), benzylbutylphthalate (BzBP), dibutylphthalate 
(DBP) and diisobutylphthalate (DIBP) are subject to EU authorization. 
DEHP, BzBP, DBP, diisononylphthalate (DINP), diisodecylphthalate 
(DIDP) and di-n-octylphthalate (DNOP) are further restricted to 0.1% in 
toys and childcare articles (EU, 2014a, 2014b). DEHP, BzBP, DBP and 
others are prohibited in cosmetics (EU, 2009). The updated Restriction 
of Hazardous Substances (RoHS) Directive limits the cumulative con-
tent of DEHP, BzBP, DBP and DIBP in electric and electronic equipment 
to 0.1% (EU, 2015). DINCH is currently regarded as a potential 
phthalate substitute with a preferred toxicological profile (Engel et al., 
2018). 
Bisphenol A (BPA) is mainly used in the manufacture of poly-
carbonate plastics and epoxy resins lining beverage and food cans. With 
more than 3 million tonnes produced every year, BPA is one of the 
Table 1 
Summary of substance groups and metals prioritized in HBM4EU and their (suspected) adverse effects. Chemical structures are given in Tables S2-S8.      
Compound (group) Main commercial use (Suspected) Toxicity References  
Phthalates and 1,2-cyclohexane 
dicarboxylic acid diisononyl ester 
(DINCH) 
Plasticizers Endocrine disruption, leading to reproduction toxicity 
and neurodevelopmental effects 
CHAP (2014), EU (2006) 
Bisphenols Manufacture of polycarbonate, epoxy 
resins and other polymers 
Endocrine disruption, associated with diabetes and 
cardiovascular diseases 
EFSA (2015), Lang et al. 
(2008), vom Saal and 
Hughes (2005) 
Per- and polyfluoroalkyl substances 
(PFASs) 
Surfactants, stain repellents, dispersants Hyperchlesterolemia, reproduction toxicity, 
immunosuppression; some substances are classified as 
persistent organic pollutants (POPs) 
EFSA (2018), UNEP (2006a, 
2016) 
Halogenated flame retardants (HFRs) Flame retardants in polymers Thyroid homeostasis disruption, neurodevelopmental 
effects; some substances are classified as POPs 
Lyche et al. (2015), UNEP 
(2006b, 2010) 
Organophosphorous flame retardants 
(OPFRs) 
Flame retardants and plasticizers in 
polymers 
Cancer (chlorinated OPFRs), neurotoxicity Reemtsma et al. (2008) 
Polycyclic aromatic hydrocarbons 
(PAHs) 
By-product of combustion processes, 
manufacture of pigments, dyes, pesticides, 
pharmaceuticals etc. 
Cancer, mutagenicity, immunosuppression, endocrine 
disruption 
Andersson and Achten 
(2015), EU (2013) 
Arylamines Manufacture of polymers, rubbers, 
adhesives, dyes, pharmaceuticals etc. 
Methemoglobinemia; cancer Neumann (2005), IARC 
(2010), Skipper et al. 
(2010) 
Cadmium Pigment production, solar panels Cancer, effects on liver and kidney, bone mineralisation EFSA (2009), IARC (2012) 
Chromium Stainless steel production, electroplating, 
paint additive, tanning agent 
Cr (VI): Cancer, effects on liver and kidney, contact 
allergen 
EFSA (2014), IARC (2012) 
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highest production volume chemicals in the world (Erler and Novak, 
2010). BPA is widely detected in humans (Calafat et al., 2008; Koch 
et al., 2012; Ye et al., 2008) and shows an estrogenic mode of action 
(Table 1). In 2015, the European Food Safety Agency (EFSA) lowered 
the tolerable daily intake to 4 μg/kg bodyweight, subject to re-assess-
ment (EFSA, 2015). In the EU, BPA has not been allowed in plastic 
infant feeding bottles since 2011 (EU, 2011), and has been phased out 
in thermal paper since 2020 (EU, 2016). It is also listed as an SVHC. 
Amongst its substitutes, bisphenols S and F are structurally similar to 
BPA, with similar toxicological concern (Eladak et al., 2015). 
As per- and polyfluoroalkyl substances (PFASs) are both water 
and oil repellent, they have had a wide range of industrial and com-
mercial applications, e.g. as surfactants, stain repellents and dispersants 
(Prevedouros et al., 2006). The main sub-groups are perfluoroalkyl 
sulfonic acids (PFSAs) and perfluoroalkyl carboxylates (PFCAs); among 
these the best studied compounds are perfluorooctane sulfonate (PFOS) 
and perfluorooctanoic acid (PFOA). Some PFASs bioaccumulate and 
biomagnify in the food chain, and incidents of PFASs in drinking water 
have been reported as well (de Vos et al., 2008; Post et al., 2012). PFASs 
are widely detected in humans, with decreasing tendencies for PFOS, 
but inconclusive developments for other PFASs (Kärrman et al., 2007; 
Gomis et al., 2017; Salthammer et al., 2018). They have been associated 
with various adverse effects (Table 1). PFOS and PFOA are globally 
restricted through the Stockholm Convention on Persistent Organic 
Pollutants (POPs), which currently also reviews perfluorohexane sul-
fonate (PFHxS). PFOA is also regulated in the EU, with a production ban 
effective in 2020 (EU, 2017a). Provisional tolerable weekly intake rates 
of 13 and 6 ng/kg body weight for PFOS and PFOA, respectively, were 
set by EFSA in 2018 (EFSA, 2018). 
Halogenated flame retardants (HFRs) and organophosphorous 
flame retardants (OPFRs) account for the majority of organic FRs 
(Alaee et al., 2003). Most FRs are added to the polymer without 
covalent bonds and can be emitted to the environment more easily than 
reactive FRs, which are covalently bound to the polymer, e.g. tetra-
bromobisphenol A (TBBPA). FRs are frequently detected in the indoor 
environment, with OPFR concentrations in dust and air usually ex-
ceeding those of HFRs by at least an order of magnitude (Cequier et al., 
2014a). However, OPFRs do not accumulate in food chains to the same 
extent as some HFRs (Greaves and Letcher, 2017). The chlorinated 
OPFRs tri(2-chloroethyl)phosphate (TCEP), tri(chloroisopropyl)phos-
phate (TCIPP) and tri(1,3-dichloroisopropyl)phosphate (TDCIPP) are 
carcinogenic or suspected to be carcinogenic; additional effects of HFRs 
and OPFRs are summarized in Table 1. Polybrominated diphenyl ethers 
(PBDEs) and hexabromocyclododecane (HBCDD) are included in the 
Stockholm Convention on POPs. PBDEs are included with the three 
commercial mixtures Penta-, Octa- and Deca-BDE, mainly consisting of 
congeners with four/five, six/seven and ten bromine atoms, respec-
tively. Dechlorane plus has been nominated to the Stockholm Con-
vention. It was also recently added to the SVHC list of EU REACH. 
TCEP, TCIPP and TDCIPP are not allowed in toys in the EU (EU, 2014c). 
Polycyclic aromatic hydrocarbons (PAHs) are emitted to the 
environment from incomplete combustion processes, which can be 
natural or anthropogenic, and petrogenic sources (Webster et al., 
2009). To a minor extent, some PAHs are also used commercially, e.g. 
in the manufacture of pigments, dyes, pesticides and pharmaceuticals 
(Abdul-Shafy and Mansour, 2016). PAHs have raised a number of 
health concerns (Table 1). The commonly applied list of 16 priority 
PAHs originally set by the US Environmental Protection Agency in 1976 
likely underestimates PAH toxicity as it does not include large molecule 
PAHs, alkylated PAHs and PAHs with heteroatoms (Andersson and 
Achten, 2015). Eight PAHs (benzo[a]pyrene, benzo[e]pyrene, benz[a] 
anthracene, chrysene, benzo[b]fluoranthene, benzo[j]fluoranthene, 
benzo[k]fluoranthene and dibenzo[a,h]anthracene) are classified as 
carcinogenic in the EU (EU, 2013). Consumer products containing any 
of these PAHs in quantities above 1 mg/kg are prohibited in the EU, 
with a lower limit of 0.5 mg/kg for toys and childcare articles (EU, 
2013). 
Arylamines are intermediates in the production of agricultural and 
pharmaceutical chemicals, polyurethanes, dyes and pigments. 2,3-, 
2,4-, 2,5- and 2,6-dimethylaniline (DMA), 2-, 3- and 4-ethylaniline 
(EA), 2-, 3- and 4-methylaniline (MA), 1- and 2-naphtylamine (NA), 2-, 
3- and 4-aminobiphenyl (ABP) are present in cigarette smoke, and 2-NA 
and 4-ABP have also been found in fumes of cooking oils (Chung, 2015; 
Sabbioni, 2017). Several arylamines have been found in indoor and 
outdoor air where aniline usually was present at higher levels than 
other arylamines (Palmiotto et al., 2001). Other sources of exposure to 
arylamines are dyes in e.g. food, textiles, inks, hair dyes and tattoos, 
food packages or pesticides synthesized from arylamines (IARC, 2010; 
Chung, 2015; Sabbioni and Hauri, 2016). The analgesic Paracetamol 
(N-acetyl-4-aminophenol) is an aniline derivative, also formed from 
aniline in human metabolism (Dierkes et al., 2014). Arylamines are 
moderately to highly toxic (Table 1). Several arylamines and their 
metabolites (e.g. 4,4-methylenebis(2-chloroaniline) (MOCA), 4,4-me-
thylenedianiline (MDA), 2,4-toluenediamine (2,4-TDA), 4-ABP, 2-MA 
and 2-methoxyaniline (2-MeOA)) are included on the SVHC list of EU 
REACH. 
Cadmium and chromium occur naturally and have had many in-
dustrial applications: Cd has been used in the production of pigments 
for glass and plastics. Its former use in the anti-corrosion plating of steel 
and Ni-Cd rechargeable batteries has decreased, but it is newly used in 
cadmium telluride solar panels. Cr is mainly used for corrosion re-
sistance in stainless steel production, electroplating and paint. Besides 
occupational situations, exposure mainly occurs through diet and ci-
garette smoke (Fagerberg et al., 2017; EFSA, 2014). While trivalent Cr 
is not toxic because it is poorly absorbed, hexavalent Cr is mutagenic 
and highly oxidative (Table 1). Both Cd and Cr (VI) have been eval-
uated as carcinogenic to humans (Table 1). Cadmium and several Cd 
salts are on the EU REACH list of SVHCs. Both Cd and Cr are severely 
restricted in their use in the EU (EU, 2006, 2015). For work places, an 
exposure limit value of 0.025 mg/m3 has been set for Cr (VI), with a 
view to lower it to 0.005 mg/m3 in the future (EU, 2017b). 
3. Materials and methods 
3.1. General approach 
The first step of the study was to establish general criteria for the 
evaluation of most suitable biomarkers, matrices and analytical 
Fig. 1. Approach to identify the most suitable biomarkers, human matrices and analytical methods for the prioritised substance groups and metals. Based on the 
evaluation, specific biomarkers and matrices will be selected for further work in HBM4EU. 
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methods (Fig. 1). In a second step, the literature was reviewed for each 
of the selected substance groups and metals, and the evaluation criteria 
were applied, resulting in a list of the most suitable biomarkers, ma-
trices and analytical methods. Based on this evaluation, certain bio-
marker and matrix combinations will be selected for the studies in 
HBM4EU. 
3.2. Criteria for the evaluation of biomarkers, matrices and analytical 
methods 
The criteria established for the evaluation of biomarkers, matrices 
and analytical methods were intended to apply to all substance groups 
and metals, as well as to potential future additions, i.e. to a variety of 
compounds with different physical–chemical properties and exposure 
pathways. Most of the selected substance groups consist of multiple 
individual compounds (Tables S2-S8). Consequently, some analytical 
methods are still subject to research, while others have been applied 
routinely in human biomonitoring studies (e.g. Haines et al., 2017). To 
account for these differences, three operational levels were defined, 
representing categories of biomarkers with A) sufficient, B) insufficient, 
C) very limited data availability in human biomonitoring. Thus, the C 
category reflects emerging interest in a compound and/or technical 
limitations in the analytical chemistry. The criteria were based on lit-
erature information and expert knowledge. 
3.3. Evaluation of biomarkers, matrices and analytical methods 
The literature search focused on studies on human biomonitoring, 
taking into account the compound-specific history of chemical analyses, 
for example transitions from single to triple quadrupole mass spectro-
metry, as well as important specifics for some compound groups, for 
example enzymes used for the deconjugation of glucuronides. No 
bioassays were included as analytical methods. In general, a non-sys-
tematic literature search was conducted in Web of Science, Scopus, 
ScienceDirect and/or PubMed, covering approximately the last 
10 years. Search terms were the compound names, including typically 
used acronyms, combined with “biomonitoring”, “human” or 
“analytical method” or filtered for these terms subsequently. Priority 
was given to publications with exhaustive information on analytical 
methods and their quality. Reference lists were used to identify original 
publications with method validation data. The biomarkers were as-
signed to the A, B and C categories depending on data availability and 
the maturity of the analytical methods. For most substances, a second 
literature search was conducted with a focus on Category B and/or C 
compounds to ensure that recently published developments in their 
analytical determination were included. The initial literature search 
yielded between 47 (OPFRs) and 976 (Cr) articles, of which 21 and 45, 
respectively, were considered further for the evaluation of biomarkers, 
matrices and analytical methods. The highest number of articles was 
considered for PFASs, i.e. 69 publications. 
Using the criteria for the evaluation of biomarkers, matrices and 
analytical methods, the information in the literature was evaluated with 
regard to the most suitable biomarker, matrix and analytical method for 
each of the selected compound groups and metals. Considering that 
some compounds occur at low levels in human matrices, particular 
attention was paid to sensitivity in terms of method detection limits 
(MDL), i.e. the limit of detection (LOD) related to a specific sample 
intake. If sensitivity was considered adequate for biomonitoring pur-
poses, uncertainty and accuracy were assessed according to the criteria, 
including information on external QA/QC, i.e. interlaboratory com-
parisons and certified reference materials. 
4. Results and discussion 
4.1. Criteria for the evaluation of biomarkers and matrices 
The criteria are summarized in Table 2, not presenting a ranked 
order. The first three criteria for the best biomarker/matrix combina-
tions address the overall purpose of linking external and internal ex-
posure. The qualitative criterion of specificity is extended to a quanti-
tative one in the second criterion according to which the biomarker 
concentration should be correlated with intake dose. This knowledge is 
not always available for emerging compounds (Category C). For ex-
ample, 2,4,6-tribromophenol was detected at a median concentration of 
Table 2 
Evaluation criteria for pairs of exposure biomarkers (EB) and matrices (M), not given in a ranked order. Categories A, B and C apply to sufficient, insufficient and very 
limited data availability, respectively, for a certain biomarker in human biomonitoring.      
Category A and B Category C  
Specificity EB/M concentrations reflect exogenous exposure. The EB/M 
concentration is an exclusive consequence of environmental/ 
occupational exposure. 
EB/M concentrations might not exclusively reflect exogenous exposure 
to the substance, but are a correct indication of exposure. 
Biological sensitivity The measured concentration of the EB/M correlates strongly with the 
substance intake dose. Variations of EB/M concentration reflect the 
variation of exposure to the substance of interest. 
The measured concentration of the EB/M is an acceptable indication of 
the substance intake dose. 
Half-life The EB/M should preferably have a half-life sufficiently long to avoid an excessive intra-individual variability in EB/M concentration measurement. 
Stability after sample 
collection 
The EB/M is stable in the sample for many hours during (refrigerated) 
transportation to the laboratory or before storage in a biobank. 
Transport conditions can be optimized easily to ensure the stability. 
If stability data is missing, stability should be assessed. For compounds 
with low stability, sample degradation can be prevented by an 
adaptation of transportation conditions or implementation of particular 
sampling operating procedures. 
Stability during storage The cryo-preservability of EB/M is sufficient to guarantee a high 
stability during storage in the biobank, usually at −20 °C. 
If stability of the EB/M is not guaranteed during storage in biobanks, it 
is recommended to analyse the sample as soon as possible. 
Matrix availability and 
sample collection 
The sample collection of the relevant matrix is not considered too 
invasive. Easy collection and transportation of the required amount of 
sample with a validated sampling protocol is beneficial. It is 
advantageous if it is possible to determine more than one EB in the 
same matrix. 
It is relatively easy to obtain a sufficient sample volume for a required 
number of samples. 
Method detection limits 
(MDL) 
The MDL of a validated analytical method is lower than commonly 
measured concentrations in the general population. The EB/M with the 
highest frequency of quantified data available is preferable. 
Only a few studies are available and the quantification might be based 
on insufficiently validated methods. 
Measurement validity The EB/M concentration in the sample is not likely to be altered by 
contamination with a ubiquitous parent substance from the 
environment preceding and during the analysis. Variations in matrix 
composition can be easily corrected for (e.g. creatinine in urine, lipids 
in serum). 
Sample contamination by a ubiquitous parent substance might occur, 
but the level of contamination is low compared to expected levels and 
special precautions can be applied to minimize the amount of 
contamination.    
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21.5 ng/g lipid weight in serum samples from Canada, but it could 
originate from multiple sources. Besides being a flame retardant, it can 
be a PBDE metabolite or formed naturally in aquatic ecosystems (Butt 
et al., 2016). 
The half-life criterion bridges the purpose of linking external and 
internal exposure to the more technical criteria that need to be fulfilled 
to generate meaningful data. Prior knowledge of the half-life and tox-
icokinetics of a biomarker in a given matrix is essential for interpreting 
the biomonitoring data, but also for the sampling design. For example, 
phthalate diesters are rapidly cleaved into monoesters and can be oxi-
dized prior to their excretion in urine, leading to primary and secondary 
metabolites as biomarkers in biomonitoring studies (Koch and Calafat, 
2009). 
The question of the most suitable matrix also involves issues of 
practicability, as described under “Matrix availability”. Persistent or-
ganic pollutants are stable enough to accumulate in lipid-rich tissues 
and blood, making human milk and serum suitable matrices for these 
compounds (WHO, 2015). However, the invasive nature of blood 
sampling sometimes limits its applicability, and matrices like nails or 
hair have been subject of research into alternatives, e.g. for Cd and 
other metals as well as HFRs (Lemos and Carvalho, 2010; Liu et al., 
2015). Nevertheless, non-invasive matrices might be in conflict with the 
criterion of specificity and biological sensitivity, thus not meeting cri-
teria of suitable EB/M combinations. Non-persistent chemicals – or 
their metabolites - are readily excreted, making urine a more suitable 
matrix. Urinary metabolites typically reflect recent exposure and may 
be misguiding in case of intermittent exposure. Moreover, excretion 
rates vary for demographic groups and with bodyweight, and con-
centrations of chemicals in urine are affected by hydration status (Hays 
et al., 2015; Bevan et al., 2017). Therefore, they are typically corrected 
for creatinine content or specific gravity (WHO, 2015). As children’s 
creatinine excretion increases with age, creatinine-correction would 
potentially introduce a bias into the data analysis of children’s urine 
samples, making specific gravity a more robust and suitable correction 
factor for this age group (Pearson et al., 2009). 
4.2. Criteria for the evaluation of analytical methods 
Method detection limits, i.e. sensitivity, and measurement validity, 
both included in Table 2, also tie into the criteria for analytical 
methods, given without a ranking in Table 3. Potential contamination 
risks have to be considered for compounds of widespread commercial 
use, such as phthalates, bisphenols or flame retardants. BDE-209, the 
fully brominated PBDE congener, was a much discussed case as blank 
issues, in combination with limited stability, affected data quality and 
consequently, impeded reliable risk assessments (Alcock et al., 2011). 
Potential contamination issues affect the robustness and comparability 
of MDLs, as specified as additional criteria related to sensitivity 
(Table 3). 
Given the low levels of many biomarkers in the general population, 
sensitivity was considered a key parameter in the evaluation criteria for 
analytical methods. It is determined by the instrumental technique, but 
also to a high degree by the sample amount available for analysis. For 
HFRs in serum, for example, MDLs in the pg/mL range usually require 
sample intakes greater than 1 mL (Cequier et al., 2013; Frederiksen 
et al., 2010a), which are not always available in biobanks or from 
multi-purpose sampling. 
4.3. Evaluation of biomarkers, matrices and analytical methods 
4.3.1. Literature summary 
The priority substances in HBM4EU cover a wide range of chemical 
groups with different physical–chemical properties. Consequently, the 
scientific literature offers a variety of analytical methods between and 
sometimes within substance groups, as summarized in Table 4. The 
references in Table 4 are not exhaustive, but represent examples of 
studies including the matrices and analytical methods summarized in 
the table. Depending on the substance group, the biomarkers in human 
biomonitoring were either parent compounds or metabolites. A wide 
spectrum of matrices has been analyzed, sometimes with different 
purposes, e.g. method development towards non-invasive sampling 
(hair, nails) or exposure analyses of specific populations (human milk). 
The analytical methods that are summarized as gas chromatography 
(GC) with mass spectrometry (MS) in Table 4 included both GC with 
low resolution (GC-LRMS) and high resolution MS (GC-HRMS) as well 
as triple quadrupole MS (GC–MS/MS). It is important to highlight that 
the approach of this study did not target the most commonly used 
biomarker, matrix or analytical method, but those fulfilling the selec-
tion criteria (Table 2; Table 3). Although experiences from e.g. 
NHANES are included in Table 4, the approach did not intend to copy 
existing selections of biomarkers, matrices and analytical methods, but 
to apply the selection criteria to state-of-the-art methodology and to 
critically discuss potential challenges. This approach resulted in a 
number of recommendable EB/M combinations and analytical methods, 
as further discussed below. 
4.3.2. Phthalates and DINCH 
Phthalates are best monitored as their monoester metabolites, in 
oxidized form or without oxidative modification (Table 5). Uptake of 
phthalates is followed by their cleavage into monoesters, oxidation in 
phase I reactions, conjugation of this secondary metabolite with glu-
curonic acid in a phase II reaction and excretion with urine (Koch and 
Calafat, 2009). In the analysis, the conjugates are cleaved, and the 
(oxidized) monoester is a suitable biomarker. In general, the simple 
monoesters (without oxidative modification) will be the biomarkers of 
choice for low molecular weight phthalates, such as diethyl phthalate 
(DEP) and DBP, whereas oxidized secondary metabolites are the bio-
markers of choice for phthalates with long alkyl chains, such as DEHP, 
DINP or DIDP (Koch et al., 2003; Koch and Calafat, 2009). This shift in 
target biomarkers (from simple to oxidized monoester metabolites) is 
mainly related to the lower water solubility of the monoesters with long 
alkyl chains, which needs to be further increased in phase I reactions 
(Koch and Calafat, 2009). Furthermore, the oxidized metabolites have 
longer elimination half-lives than the simple monoesters, which is in 
agreement with the criteria for half-lives in Table 2. The longer half- 
lives allow detection of exposures in the past or cumulative exposures 
(Wittassek et al., 2011). For DINCH, the oxidized monoesters are more 
suitable biomarkers than the simple monoesters, amongst other criteria 
because of half-lives of 12–24 h (Koch et al., 2013). In addition, the 
oxidized metabolites are not prone to external contamination 
(Wittassek et al., 2011). Otherwise the risk of external contamination 
during sampling and sample preparation is high, due to the wide use of 
phthalates as plasticizers, and needs to be considered in sampling and 
QA/QC strategies (Koch and Calafat, 2009). 
For some phthalates, such as DINP and DIDP, several isomers exist. 
Their quantification is typically based on analytical standards of single 
isomers whereas all isomeric peaks are integrated in the urine sample. 
Having an isomeric composition of the alkyl side chain similar to DINP, 
the analysis of DINCH and its secondary oxidized metabolites is com-
parable to that of DINP (Koch et al., 2013). Quantification should in-
tegrate over all isomers with respective oxidative modifications, and 
the standards should be derived from the major alkyl chain isomer. 
Based on the metabolism and elimination characteristics described 
above, urine is the preferred human matrix for biomonitoring of 
phthalates and DINCH (Esteban and Castaño, 2009). Phthalate meta-
bolites correlate in serum and urine, indicating that serum would also 
be a suitable matrix. However, the concentrations in serum are con-
siderably lower (Frederiksen et al., 2010b). Furthermore, degradation 
and external contamination need to be closely monitored in serum 
analyses (Koch and Calafat, 2009; Calafat et al., 2015), jeopardizing the 
criterion of measurement validity (Table 2). Phthalates and their me-
tabolites were also detectable in human milk, but those studies were 
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Table 3 
Evaluation criteria for analytical methods for human biomonitoring. Categories A, B and C apply to sufficient, insufficient and very limited data availability, 
respectively, in human biomonitoring. The criteria are not given in a ranked order. EB: Exposure biomarker. M: Matrix.       
Category A Category B Category C  
Sample preparation Sample preparation procedures are well 
established and applied on a routine basis for 
relevant biological matrices. 
Appropriate sample preparation procedures may 
be available to some extent, but have not 
necessarily been established for all EB/M 
combinations. A certain level of development 
(mainly adaptation) could be necessary. 
Sample preparation procedures are typically 
not yet available and have to be developed. 
The effort needed for this development will 
depend on the possible adaptation of an 
existing protocol (e.g. for adding new 
substances from an already known family). 
Standards The use of standards of target EBs and internal 
standards (among these isotopically labelled 
standards where relevant), is applied. They are 
commercially available at reasonable costs. 
The use of standards of target EBs and internal 
standards (among these isotopically labelled 
standards where relevant), is applied where 
possible. Standards are not necessarily 
commercially available or might be offered by 
only one or few suppliers. 
Determination of this substance might be the 
first tentative identification of the EB/M. 
Standards might not be commercially 
available. 
Validation The method is well-established in multiple 
laboratories. Comprehensive validations have 
been performed. Participation in inter- 
laboratory comparisons and/or use of certified 
materials is in place (if available for the EB/M). 
The method is established and full within 
laboratory validation has been carried out in 
some research laboratories. Concentrations might 
still be reported using methods subjected to less 
rigorous validation procedures. Large-scale 
studies and interlaboratory comparisons are 
expected. 
No method validation is expected. Assessment 
of critical parameters might be in progress. 
Selectivity A low extent of interferences has been 
demonstrated. The measured concentrations 
are that of the EB/M. 
Potential interferences might not be fully 
controlled for some EB/M. 
Selectivity has not necessarily been assessed. 
Sensitivity  
- Limits of detection 
(LOD) 
LODs have been determined for each EB/M and 
have usually been reported in comprehensive 
validations. 
LODs are available for some individual EB/M, but 
not necessarily for all EBs and all matrices of 
interest for human biomonitoring. 
Highly dependent on availability of standards. 
When available, the LODs might have been 
determined for individual studies, but not as 
part of a validation procedure.  
- Quantifiable 
compounds 
In general, LODs have been proven to be 
sufficiently below the concentrations in a high 
proportion of the samples of a population. 
LODs may appear higher than the expected 
exposure, but enable quantification of most 
biomarkers in a reasonable number of samples of 
the population. Risk of low detection rates, and 
subsequent biased upper bound risk assessment. 
Quantification is reliable only when the 
standard is available. For some compounds, 
only semi-quantitative determinations are 
possible.  
- Robustness Limited variation in the LODs between samples 
or over time. Controlled environment- 
laboratory conditions (e.g. low background 
levels). 
Some variation in LODs can occur (e.g. variable 
blanks and/or instrument performance). 
High variation in LODs can occur or absent/ 
insufficient information available to properly 
quantify this parameter. Interferences cannot 
be ruled out.  
- Comparability Similar LODs have been obtained by most 
laboratories. 
Variability in LODs exists, for example due to 
different analytical approaches for the 
determination of the EB/M. 
Low comparability of LODs or absence of 
information. Subject to method development 
and validation. 
Accuracy  
- Accuracy – availability 
of QC measures 
The accuracy has usually been assessed using 
external QC measures such as certified 
reference materials or relevant interlaboratory 
comparisons. 
The accuracy has mainly been assessed using 
internal QC measures, recovery tests or 
comparisons with an independent analytical 
method, although some external QC measures 
might be available for some EB/M. 
The accuracy has usually not been evaluated 
yet.  
- Accuracy - assessment The accuracy is within the limits given by 
guidelines for validation of analytical methods  
(e.g. ≤ 20% deviation, depending on the 
concentration level and EB/M). 
The accuracy might be compromised by several 
factors (e.g. internal standards, blank 
contamination at low concentrations). A wider 
range of accuracies is expected (e.g. ≤ 40% 
deviation). 
The accuracy has usually not been assessed, 
but indications from similar EB might be 
available. High uncertainty must be expected. 
Recovery The EB recoveries are usually in the range of 
80–120%. If outside this range, the use of 
proper internal standards compensates the 
deviations. 
Variable recoveries might be expected (e.g. 
50–150%). There is a stronger need to 
compensate the deviations with a proper internal 
standard. 
Recoveries have rarely been assessed. 
Range/Linearity The method provides acceptable precision and 
accuracy for the relevant concentration range. 
The linear range has been evaluated for the 
determination of the relevant EB/M. 
The method mainly provides acceptable precision 
and accuracy for higher concentrations. 
Awareness exists of potential issues at low 
concentrations. The linear range has usually been 
evaluated for the relevant EB/M, although less 
attention might have been paid to keeping all 
determined concentrations within the linear 
range. 
Optimal working range has rarely been 
evaluated. 
Robustness  
- Response to small 
changes in the 
analytical process 
The robustness has been assessed, and only 
small variations within acceptable limits have 
been identified due to minor changes in the 
analytical procedure/conditions. 
The robustness has been assessed, and variations 
can occur due to several factors (e.g. EB stability, 
instrument performance, environment and/or 
operating conditions). 
The robustness has likely not been assessed. 
Any significant variations, which could affect 
the analytical result, should be reported.  
- Method precision/ 
Repeatability 
The repeatability/intermediate precision has 
been evaluated according to common 
guidelines. It is within an acceptable range. 
Control charts are usually used for the 
assessment of precision. 
The repeatability/intermediate precision has 
often been assessed, but the standard deviations 
can be higher than the recommendations given in 
the guidelines for validation of analytical 
methods. 
The repeatability/intermediate precision has 
likely not been assessed.    
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related to the specific exposure of infants (Fromme et al., 2011). 
The analysis of the phthalate and DINCH metabolites is best per-
formed by LC-MS/MS, offering sufficient sensitivity for biomonitoring 
of the general population. The generally low levels in the general po-
pulation require MDLs of approximately 100–300 pg/mL, which is 
technically feasible with state-of-the-art instrumentation and sample 
volumes of ≤ 1 mL. All relevant metabolites can be covered with a 
single LC-MS/MS method. GC–MS analysis after derivatization has been 
applied to separate metabolites of di(2-propylheptyl) phthalate 
(DPrHpP) from DIDP metabolites (Gries et al., 2012). 
The compounds can be extracted and separated by solid phase ex-
traction (SPE), either online or off-line, or the deconjugated samples are 
directly analysed by LC-MS/MS (Müllerová et al., 2016). Deconjugation 
is best achieved by enzymatic hydrolysis with arylsulfatase-free E.coli 
K12 β-glucuronidase. Some glucuronidase enzymes might hydrolyse 
phthalate ester bonds in the parent phthalates due to arylsulfatase or 
esterase side activities, which has to be avoided (Blount et al., 2000; 
Feng et al., 2015; Koch et al., 2018). Thus, the use of Helix pomatia β- 
glucuronidase might lead to false positives when monoester metabolites 
are analysed. Native and labelled standards are commercially available 
for most of the prioritized biomarkers, as are certified reference mate-
rials (Schantz et al., 2015). 
4.3.3. Bisphenols 
The bisphenol parent compounds were identified as the most sui-
table biomarkers for human biomonitoring (Table 6), determined after 
hydrolysis of conjugates, typically using H. pomatia or E. coli K12 β- 
glucuronidase enzymes, some of which also present arylsulfatase ac-
tivity. Most bisphenols are rapidly metabolized, mainly to their glu-
curonidated form, and excreted as conjugates. The half-lives of bi-
sphenol A and S conjugates in humans were determined to be less than 
six and seven hours, respectively (Dekant and Völkel, 2008; Oh et al., 
2018). However, deconjugation can take place in the body, and since 
only the parent compound can bind to the estrogen receptor, the pre-
sence of unconjugated bisphenols is discussed as a measure of toxic 
potential (Ginsberg and Rice, 2009). Separate analyses of free and 
conjugated bisphenols at trace levels have been attempted, but proven 
challenging due to the very low levels of the free forms requiring 
maximum sensitivity and posing a risk of external contamination 
(Markham et al., 2010; Liao and Kannan, 2012). However, for means of 
quantitative exposure assessments, the analyses of total bisphenol levels 
appear sensitive and robust (Dekant and Völkel, 2008). 
For bisphenol F, more specifically the isomer 4,4′-bisphenol F, a 
natural occurrence in mustard has been reported, leading to a daily 
intake similar to that of BPA and posing the question of a distinction 
between natural and anthropogenic sources of bisphenol F (Dietrich 
and Hengstler, 2016). The isomer 2,2′-bisphenol F is a biomarker of 
non-natural exposure to bisphenol F (Zoller et al., 2016). Bisphenols S 
and F have been analysed more frequently than the remaining bi-
sphenols in Table 6 and have been included in the NHANES since 2013 
(CDC, 2018), hence their Category B classification. 
Urine was the matrix of choice to study exposure of the general 
population. Techniques are available to analyse bisphenols in other 
human matrices (Table 4), but these studies have usually been directed 
at specific populations or research questions (Gerona et al., 2013; 
Zimmers et al., 2014). However, urine analyses alone have been con-
sidered unsuitable to assess the full toxicokinetics of bisphenols 
(Vandenberg et al., 2014). 
The selected analytical methods are based on LC-MS/MS, combined 
with a variety of extraction and clean-up methods, for example online- 
solid phase extraction (SPE). However, GC–MS approaches, in parti-
cular GC–MS/MS, appear equally suitable according to the selection 
criteria (Table 3), as they provide low detection limits and low external 
contamination levels (Zhang et al., 2011; Deceuninck et al., 2014). 
Isotope-labelled standards of bisphenols are increasingly available in-
cluding those for bisphenols A, S, F and B. 
Based on sample intakes of 100–500 μl, MDLs of 20–100 pg/mL are 
achievable for bisphenols A, S and F (Liao et al., 2012; Ye et al., 2015; 
Wang et al., 2019); however, higher and lower sample intakes have 
been described as well (Heffernan et al., 2016; Rocha et al., 2016). The 
Category C bisphenols are generally present in lower levels (Ye et al., 
2015). However, an MDL of 5 pg/mL has been reported for bisphenol 
AF (Heffernan et al., 2016; Rocha et al., 2016). 
Thus, analytical methods published today will benefit from further 
development towards higher sensitivity, greater accuracy (by using 
labelled standards) and the more frequent inclusion of other bisphenols. 
Given the widespread use of bisphenols, control of external con-
tamination is important at all pre-analytical and analytical stages to 
ensure measurement validity. Based on the human biomonitoring in-
formation currently available, only BPA was considered a category A 
compound. 
4.3.4. Per- and polyfluoroalkyl substances (PFASs) 
Most PFSAs and PFCAs are persistent and can be measured directly 
as biomarkers of exposure (Table 7). However, PFSAs and PFCAs can 
also be transformation products of less persistent precursors, e.g. 
fluorotelomer alcohols (FTOHs), perfluoroalkyl sulfonamides (FOSAs) 
and perfluoroalkyl sulfonamidoethanols (FOSEs) (Table S4). Thus, de-
tection of PFSAs and PFCAs in human samples integrates direct ex-
posure to these compounds and exposure to precursors, which implies 
that strictly speaking, the first EB/M criterion of specificity is not met 
for all PFSAs and PFCAs. Furthermore, the precursors are not always 
transformed quantitatively, and some can also be detected in human 
samples (Vorkamp et al., 2014). Finally, other transformation products 
than PFSAs and PFCAs are detectable in human samples, for example N- 
methyl-perfluorooctane sulfonamidoacetate (MeFOSAA) or N-ethyl- 
perfluorooctane sulfonamidoacetate (EtFOSAA), which are transfor-
mation products of N-methyl-perfluorooctane sulfonamidoethanol 
(MeFOSE) and N-ethyl-perfluorooctane sulfonamidoethanol (EtFOSE) 
(Buck et al., 2011; Vorkamp et al., 2014). For 8:2 FTOH, 8:2 FTOH 
sulfate has been suggested as an applicable biomarker (Dagnino et al., 
2016). While half-lives of serum elimination are in the order of years for 
Table 6 
Prioritized biomarkers for bisphenols. Categories A, B and C apply to sufficient, insufficient and very limited data availability, respectively, of a certain biomarker in 
human biomonitoring. Matrix and analytical method of choice were urine and high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS), 
respectively, for all biomarkers.     
Biomarker Category Reference  
Bisphenol A A Calafat et al. (2008), Heffernan et al. (2016), Koch et al. (2012), Rocha et al. (2016), Wang et al. (2019), Ye et al. (2015) 
Bisphenol S B Heffernan et al. (2016), Liao et al. (2012), Ndaw et al. (2018), Rocha et al. (2016), Wang et al. (2019) 
Bisphenol F B Heffernan et al. (2016), Rocha et al. (2016), Wang et al. (2019), Ye et al. (2015) 
Bisphenol B C Heffernan et al. (2016) 
Bisphenol P C Rocha et al. (2016) 
Bisphenol Z C 
Bisphenol AP C 
Bisphenol AF C Heffernan et al. (2016), Rocha et al. (2016), Ye et al. (2015) 
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PFHxS, PFOS and PFOA, short-chain PFASs, such as perfluorobutane 
sulfonate (PFBS) and perfluorobutanoic acid (PFBA), appear less per-
sistent and bioaccumulative (Gomis et al., 2018; Olsen et al., 2007). As 
PFASs differ in their toxicity (Gomis et al., 2018) it is advisable for risk 
assessment purposes to address a suite of substances, while bearing in 
mind that transformation processes take place which limit EB specifi-
city. 
Serum, plasma or whole blood are the matrices of choice for all 
PFAS compounds, and relatively small volumes are necessary for ac-
ceptable MDLs. In general, published detection limits are sufficiently 
low for human biomonitoring. Based on sample intakes of 25–150 μl, 
MDLs for most PFASs are usually as low as 2–100 pg/mL (Haug et al., 
2009; Gao et al., 2018; Kato et al., 2018). For the analysis of fluor-
otelomer acids and 8:2 FTOH sulfate, 500 μl of serum were used, with 
corresponding MDLs  <  100 pg/mL (Dagnino et al., 2016; Nilsson 
et al., 2013). Slightly higher MDLs of 400 pg/mL were reported for 
MeFOSE and EtFOSE (Kuklenyik et al., 2005), but further method de-
velopment might improve the currently documented sensitivity. PFSAs 
and PFCAs can also be measured in blood spots (Kato et al., 2009; Ma 
et al., 2013; Poothong et al., 2019), which would improve sample 
availability for infants. Table 7 includes a reference to whole blood for 
the analysis of fluorotelomer saturated and unsaturated carboxylic 
acids. Serum and plasma would likely be suitable matrices for these 
compounds as well, however, a method with full validation and QA/QC 
information is not yet available in the literature. 
PFASs have also been analysed in human milk (Kärrman et al., 
2007; Thomsen et al., 2010). However, the concentrations in milk are 
usually considerably lower than in serum, which might challenge 
MDLs, besides the obvious drawback of only presenting a part of the 
general population. For these reasons, human milk is not evaluated as 
the primary matrix in this context. Some studies exist on PFSAs and 
PFCAs in urine (Hartmann et al., 2017). This might be a relevant matrix 
for the short-chain PFSAs and PFCAs with shorter half-lives, but more 
information will be needed prior to a re-evaluation of this EB/M com-
bination. 
The analytical methods are rather uniform for all PFASs and include 
protein precipitation, clean-up and LC-MS/MS analysis using isotope- 
labelled internal standards where available. The literature survey in-
dicates that multi-methods addressing many PFASs together are feasible 
for this compound group. All biomarkers except 8:2 FTOH sulfate are 
commercially available and isotope-labelled standards are obtainable 
for some representatives of each PFAS-subgroup. However, QA/QC 
measures lack the availability of interlaboratory comparisons and cer-
tified reference materials beyond the most commonly measured PFSAs 
and PFCAs. Contamination from fluorine-containing materials such as 
polytetrafluoroethylene (PTFE) has to be avoided during sampling and 
sample processing. In addition to compound-specific analyses, sum 
parameters, e.g. total, inorganic or extractable organic fluorine, can be 
Table 7 
Prioritized biomarkers and human matrices for per- and polyfluoroalkyl substances (PFASs). Categories A, B and C apply to sufficient, insufficient and very limited 
data availability, respectively, of a certain biomarker in human biomonitoring. The analytical method of choice was high performance liquid chromatography- 
tandem mass spectrometry (LC-MS/MS) for all biomarkers.      
Biomarker Category Matrix Reference  
PFSAs: PFBS; PFHxS; PFHpS; PFOS; PFDS a A Serum; plasma; 
whole blood 
Gao et al. (2018), Haug et al. (2009), Nilsson et al. 
(2013), Poothong et al. (2017) 
PFCAs: PFBA; PFPeA; PFHxA; PFHpA; PFOA; PFNA; PFDA; PFUnDA; PFDoDA; PFTrDA; 
PFTeDA b 
A Serum; plasma; 
whole blood 
Perfluoro-1-octaperfluoro-1-octane sulfonamide (FOSA); N-methyl-perfluoro-1-octane 
sulfonamide (N-MeFOSA) 
B Serum; plasma; 
whole blood 
Gao et al. (2018), Haug et al. (2009), Kuklenyik et al. 
(2005), Nilsson et al. (2013), Poothong et al. (2017) 
N-methyl-perfluorooctane sulfonamidoacetate (MeFOSAA); N-ethyl-perfluorooctane 
sulfonamidoacetate (EtFOSAA) 
B Serum Gao et al. (2018), Kato et al. (2018), Kuklenyik et al. 
(2005), Vorkamp et al. (2014) 
8:2 polyfluoroalkyl phosphoric acid diesters (8:2 diPAP) B Serum; plasma, 
whole blood 
Gao et al. (2018), Poothong et al. (2017) 
Fluorotelomer sulfonic acids (FTSAs): 4:2 FTSA; 6:2 FTSA; 8:2 FTSA B Serum Gao et al. (2018) 
Fluorotelomer carboxylic acids (FTCAs): 5:3 FTCA; 7:3 FTCA B Whole blood c Nilsson et al. (2013) 
Fluorotelomer unsaturated carboxylic acids (FTUCAs): 6:2 FTUCA; 8:2 FTUCA; 10:2 
FTUCA 
B Whole blood c 
Ammonium 4,8-dioxa-3H-perfluorononanoate (ADONA) B Serum Kato et al. (2018) 
Perfluoroalkyl phosphoric acid monoesters (monoPAPs): 6:2 monoPAP; 8:2 monoPAP C Serum; plasma Gao et al. (2018), Poothong et al. (2017) 
Perfluoroalkyl phosphoric acid diesters (diPAPs): 6:2 diPAP; 6:2/8:2 diPAP C Serum; plasma; 
whole blood 
N-ethyl-perfluoro-1-octanesulfonamide (N-EtFOSA) C Serum Gao et al. (2018), Haug et al. (2009), Kuklenyik et al. 
(2005) 
N-methyl-perfluorooctane sulfonamidoethanol (MeFOSE); N-ethyl-perfluorooctane 
sulfonamidoethanol (EtFOSE) 
C Serum Kuklenyik et al. (2005) 
Perfluoroalkyl phosphonic acid: PFHxPA; PFOPA; PFDPA d C Serum; plasma; 
whole blood 
Gao et al. (2018), Poothong et al. (2017) 
PFCAs: PFHxDA; PFODA e C Serum Gao et al. (2018) 
FTCAs: 6:2 FTCA; 8:2 FTCA; 10:2 FTCA C Serum Dagnino et al. (2016) g 
8:2 fluorotelomer alcohol sulfate (8:2 FTOH sulfate) f C Serum 
Bis(perfluorohexyl)phosphinic acid (C6/C6 PFPiA); bis(perfluorohexyloctyl)phosphinic 
acid (C6/C8 PFPiA); bis(perfluorooctyl)phosphonic acid (C8/C8 PFPiA) 
C Serum Gao et al. (2018) 
Ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoate (GenX) C Serum Kato et al. (2018) 
a Perfluorobutane sulfonate (PFBS); perfluorohexane sulfonate (PFHxS); perfluoroheptane sulfonate (PFHpS); perfluorooctane sulfonate (PFOS); perfluorodecane 
sulfonate (PFDS). 
b Perfluorobutanoic acid (PFBA); perfluoropentanoic acid (PFPeA); perfluorohexanoic acid (PFHxA); perfluoroheptanoic acid (PFHpA); perfluorooctanoic acid 
(PFOA); perfluorononanoic acid (PFNA); perfluorodecanoic acid (PFDA); perfluoroundecanoic acid (PFUnDA); perfluorododecanoic acid (PFDoDA); per-
fluorotridecanoic acid (PFTrDA); perfluorotetradecanoic acid (PFTeDA). 
c Serum or plasma would likely be suitable matrices as well, but insufficient information is available at present. 
d Perfluorohexyl phosphonic acid (PFHxPA); perfluorooctyl phosphonic acid (PFOPA); perfluorodecyl phosphonic acid (PFDPA). 
e Perfluorohexadecanoic acid (PFHxDA); perfluorooctadecanoic acid (PFODA). 
f Biomarker for 8:2 FTOH. 
g Dagnino et al. (2016) used LC-Time of Flight (TOF)-MS instead of LC-MS/MS.  
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determined including total oxidizable precursor analysis (TOPA) (Houtz 
and Sedlak, 2012). These can provide supplementary information if 
standardized for analysis. 
4.3.5. Halogenated flame retardants (HFRs) 
The evaluation included 14 biomarkers (or groups of biomarkers) 
for HFRs which had been determined in human samples and for which 
quality assurance information was available (Table 8). All biomarkers 
were identical with the parent compounds. Regarding the PBDEs, BDE- 
47, BDE-153 and BDE-209 were considered the main biomarkers, re-
flecting a combination of highest exposure and strongest bioaccumu-
lation (Geyer et al., 2004; Thuresson et al., 2006). However, it is de-
batable if the half-life of BDE-209 of approximately 15 days is 
sufficiently long to avoid large variation among individuals (Table 2) 
(Thuresson et al., 2005). In contrast, the elimination half-lives of BDE- 
47 and BDE-153 in humans were calculated as 1.8 and 6.5 years, re-
spectively (Geyer et al., 2004). However, lower brominated PBDE 
congeners will not fully meet the EB/M criteria (Table 2) if they also are 
transformation products of higher brominated congeners in addition to 
reflecting exogenous exposure. 
Of the HBCDD isomers, α- and γ-HBCDD were determined most 
frequently in human samples. However, the EB/M criterion of bio-
marker concentrations reflecting exogenous exposure is also challenged 
in this case since bioisomerization has been shown (Szabo et al., 2010), 
leading to differences in HBCDD profiles between exposure sources and 
human samples. Thus, HBCDD only fulfills the EB/M criteria if ΣHBCDD 
is considered. The elimination half-life of ΣHBCD was 64 days (Geyer 
et al., 2004). Little is known of the transformation of other HFRs, which 
were all categorized as B or C compounds, i.e. compounds with in-
sufficient biomonitoring or exposure data. 2,3,4,5-Tetrabromobenzoic 
acid has been analysed as a biomarker for EH-TBB in urine (Hoffman 
et al., 2014). Thus, re-evaluations of the B and C cases might lead to 
changes in the prioritized biomarkers and matrices as new knowledge 
becomes available. 
Serum was evaluated to be the matrix of choice for the biomoni-
toring of HFRs in the general population. Human milk has also been 
analysed widely and its higher lipid content favours accumulation of 
lipophilic HFRs (Čechova et al., 2017; Siddique et al., 2012). Further-
more, larger sample volumes can be available, which reduces sensitivity 
issues. The serum analyses are based on relatively large sample 
amounts of roughly 1–5 mL in order to reach acceptable MDLs, which 
usually are 0.1–1 ng/g lipids, sometimes with MDLs of BDE-209 ex-
ceeding those of lower brominated PBDEs (Butt et al., 2016; Gao et al., 
2016; He et al., 2018). Higher MDLs of 2–20 ng/g lipids usually exist for 
decabromodiphenyl ethane (DBDPE) (Cequier et al., 2013; Gao et al., 
2016). Likewise, higher MDLs have been reported for other B and C 
compounds for which little information is available and that will ben-
efit from further method development (Butt et al., 2016; Li et al., 2017). 
In the NHANES programme, pooled serum samples have been used 
since 2004 for the analysis of PBDEs to increase the sample amount 
(CDC, 2018). 
Lipids should be removed from the extracts by e.g. acid silica or gel 
permeation chromatography (GPC), the latter being suitable for acid- 
sensitive HFRs, e.g. BEH-TEBP (Covaci et al., 2011). 13C-labelled 
standards are used increasingly when other masses than those of bro-
mine ions (m/z 79 and 81) are targeted. While GC-LRMS (ECNI) is a 
suitable method for PBDEs and other HFRs (Table 8), except HBCDD 
and phenolic compounds, recent developments also include the use of 
GC-HRMS or GC–MS/MS (e.g. Čechová et al., 2017; Sochorová et al., 
2017), offering low MDLs, high specificity, and if run in Electron Io-
nization (EI) mode, the possibility to use 13C-labelled standards. For 
HBCDD isomers, TBBPA and other bromophenols, the analytical 
methods evaluated as state-of-the-art include LC-MS/MS with negative 
electrospray ionisation 
It was a general outcome of the HFR evaluation that QA/QC in-
formation was insufficient, even for PBDEs which are generally per-
ceived as well-studied compounds. The analysis of BDE-209 often re-
sulted in lower precision and accuracy than that of other PBDEs, 
combined with more frequently occurring blanks (e.g. Alcock et al., 
2011; Guo et al., 2018). External contamination can also be an issue for 
current-use HFRs analysed as parent compounds, which would chal-
lenge the method validity criterion (Table 2). Developments are on-
going towards alternative, non-invasive matrices, but concentrations in 
e.g. hair and nails are difficult to interpret and thus in conflict with 
criteria of specificity and biological sensitivity in Table 2. The number 
of HFRs for which analytical methods are available is still small con-
sidering the large number of brominated FRs currently in use (Covaci 
et al., 2011). Because of the chemical heterogeneity of the HFR group, 
method extensions or multi-methods are not easily possible, but each 
compound requires its own method optimization. 
Table 8 
Prioritized biomarkers, human matrices and analytical methods for halogenated flame retardants (HFRs). Categories A, B and C apply to sufficient, insufficient and 
limited data availability, respectively, of a certain biomarker in human biomonitoring. GC–MS (ECNI): Gas chromatography-low resolution mass spectrometry with 
electron capture negative ionization. LC-MS/MS: High performance liquid chromatography-tandem mass spectrometry.       
Biomarker Category Matrix Instrumental 
analysis 
Reference  
Polybrominated diphenyl ethers (PBDEs): BDE-47, BDE- 
153, BDE-209 
A Serum a GC–MS (ECNI) Ali et al. (2013), Butt et al. (2016), Cequier et al. (2013), Gao et al. 
(2016), Guo et al. (2018), He et al. (2013), Li et al. (2017), van den Berg 
et al. (2017) 
Hexabromocyclododecane (HBCDD) isomers A Serum a LC-MS/MS Butt et al. (2016) 
Tetrabromobisphenol A (TBBPA) A Serum LC-MS/MS Hayama et al. (2004), Sochorová et al. (2017) 
Dechlorane plus isomers B Serum a GC–MS (ECNI) Cequier et al. (2013), Guo et al. (2018), He et al. (2013) 
2-Ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB) B Serum a GC–MS (ECNI) Butt et al. (2016), Guo et al. (2018) 
Bis(2-ethylhexyl) tetrabromophthalate (BEH-TEBP) B Serum a GC–MS (ECNI) Ali et al. (2013), Butt et al. (2016), Guo et al. (2018), He et al. (2013) 
1,2-Bis(2,4,6-tribromophenoxy)ethane (BTBPE) B Serum a GC–MS (ECNI) Ali et al. (2013), Cequier et al. (2013), Gao et al. (2016), Guo et al. 
(2018) 
Decabromodiphenyl ethane (DBDPE) B Serum a GC–MS (ECNI) Ali et al. (2013), Cequier et al. (2013), Gao et al. (2016), Guo et al. 
(2018), Sochorová et al. (2017) 
Hexabromobenzene (HBB) B Serum a GC–MS (ECNI) Cequier et al. (2013), Gao et al. (2016), Li et al. (2017), Sochorová et al. 
(2017) 
Pentabromotoluene (PBT) B Serum a GC–MS (ECNI) Gao et al. (2016), Li et al. (2017), Sochorová et al. (2017) 
Pentabromoethylbenzene (PBEB) B Serum a GC–MS (ECNI) 
2,3,5,6-Tetrabromo-p-xylene (p-TBX) C Serum a GC–MS (ECNI) Li et al. (2017) 
Tetrabromoethylcyclohexane (DBE-DBCH) C Serum a GC–MS (ECNI) Guo et al. (2018) 
Dechloranes 602 and 603 C Serum a GC–MS (ECNI) Cequier et al. (2013) 
2,4,6-Tribromophenol C Serum LC-MS/MS Ali et al. (2013), Butt et al. (2016), Sochorová et al. (2017) 
a Human milk has been evaluated as an equally suitable matrix for lipophilic HFRs.  
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4.3.6. Organophosphorous flame retardants (OPFRs) 
The trialkyl and triarylphosphate esters are less persistent than the 
HFRs and readily metabolized. Their dialkyl or diarylphosphate esters 
have been analyzed as the main biomarkers for human biomonitoring 
(Cequier et al., 2014b; Van den Eede et al., 2013) (Table 9). Although 
the group of OPFRs has been studied in the environment for many years 
(Reemtsma et al., 2008), their biomonitoring is still an issue of research 
and development. 
Recent studies have revealed a more complex group of metabolites 
and thus potential biomarkers for biomonitoring, besides the dialkyl 
and diarylphosphate esters: For example, bis(chloroisopropyl) phos-
phate (or bis(1-chloro-2propyl) phosphate; BCIPP) and 1-hydroxy-2- 
propyl-bis(1-chloro-2-propyl)phosphate (BCIPHIPP) are both metabo-
lites of TCIPP (He et al., 2018; Phillips et al., 2018; Van den Eede et al., 
2013). For tris(2-butoxyethyl) phosphate (TBOEP), hydroxylated me-
tabolites have also been identified as metabolites besides the diester bis 
(2-butoxyethyl) phosphate (BBOEP) (van den Eede et al., 2013). Ad-
ditional phase I and phase II metabolites were observed for all OPFRs 
(van den Eede et al., 2013). The presence of several metabolites does 
not necessarily conflict with the criteria in Table 2, as long as the 
metabolites qualitatively and quantitatively reflect exogeneous ex-
posure of a defined parent compound. However, the current identifi-
cation of most suitable biomarkers (Table 9) might be preliminary as 
research into metabolite identification continues. 
Regarding the criteria in Table 2, it is more problematic that some 
biomarkers are metabolites of several OPFRs and thus not reflective of 
exposure to a specific parent compound. Diphenyl phosphate (DPHP) 
was found to be a biomarker of several aryl-OPFRs rather than of tri-
phenyl phosphate (TPHP) specifically, as it could also result from 2- 
ethylhexyl diphenyl phosphate (EHDPHP), resorcinol bis(diphenyl) 
phosphate, isopropyl triphenyl phosphate (i,p-TPHP) and probably 
other aryl-OPFRs (van den Eede et al., 2016; He et al., 2013; Phillips 
et al., 2018). Thus, DPHP does not fully meet the criterion of specificity. 
In addition, the current literature is not always specific with regard to 
isomers of tricresyl phosphate (TMPP) and their metabolites. Little is 
known about the stability of the OFPR urinary biomarkers, but in-
dications exist of half-lives in the order of hours (Hammel et al., 2016). 
According to the current state of knowledge and applying the cri-
teria in Table 2 and Table 3, urine is the preferred matrix and LC-MS/ 
MS a suitable instrumental technique for most OPFRs. Sample intakes 
varied considerably between studies, e.g. 400 μl in the NHANES pro-
gramme (Ospina et al., 2018) and 5 mL in a German biomonitoring 
study (Fromme et al., 2014). Resulting MDLs ranged between ap-
proximately 50 and 3000 pg/mL for most metabolites, in the studies 
referred to in Table 9. For some metabolites, such as bis(2-chloroethyl) 
phosphate (BCEP) and BCIPP, GC–MS/MS might reach comparable 
sensitivity after derivatization (Schindler et al., 2009). 
Other matrices than urine have also been analysed, targeting both 
parent compounds and metabolites, but usually in studies addressing 
specific research questions, for example comparisons between matrices 
or compound groups (Li et al., 2017; Sundkvist et al., 2010). Deuterated 
standards are commercially available for many diester metabolites. The 
NHANES studies, for example, include deuterated standards of all target 
analytes (Ospina et al., 2018). 
4.3.7. Polycyclic aromatic hydrocarbons (PAHs) 
PAHs undergo oxidation and conjugation in phase I and phase II 
reactions, similarly to the metabolism reactions described for phtha-
lates. 1-Hydroxypyrene is the main phase I metabolite of pyrene 
(Table 10) and has been used as general surrogate urinary biomarker 
for PAH exposure from both environmental and occupational sources 
(Esteban and Castaño, 2009; Jongeneelen, 2014). Analogously, hydro-
xylated metabolites of naphthalene, fluorene, phenanthrene and chry-
sene are suitable PAH urinary biomarkers (Li et al., 2014; Onyemauwa 
et al., 2009). However, 1-hydroxynaphthalene can also be a metabolite 
of the insecticide carbaryl and should be assessed in combination with 
2-hydroxynapthalene, which is a specific biomarker for naphthalene 
exposure (Meeker et al., 2007). The hydroxylated metabolites of benzo 
[a]pyrene and benz[a]anthracene have been detected in urine as well 
(Barbeau et al., 2014; Onyemauwa et al., 2009; Xu et al., 2004), 
however, they are excreted to a minor extent in urine, with the con-
sequence of generally low concentrations (Jacob and Seidel, 2002). 
Haemoglobin and albumin adducts of benzo[a]pyrene have been ana-
lysed and detected in workers (e.g. Pastorelli et al., 2000). 
A variety of parent PAHs have also been monitored in serum (Boada 
et al., 2015). The authors concluded that serum was a less suitable 
matrix for PAH biomonitoring because of large inter-individual varia-
bility in the metabolism of PAHs. This might challenge the half-life 
criterion in Table 2. Furthermore, the risk of contamination conflicts 
with the measurement validity (Table 2). The analysis of metabolites in 
Table 9 
Prioritized biomarkers for organophosphorous flame retardants (OPFRs). Categories B and C apply to insufficient and very limited data availability, respectively, of a 
certain biomarker in human biomonitoring. Matrix and analytical method of choice were urine and high performance liquid chromatography-tandem mass spec-
trometry (LC-MS/MS), respectively, for all biomarkers.      
Biomarker Parent compound Category Reference  
Bis(2-chloroethyl) phosphate (BCEP) Tri(2-chloroethyl) phosphate 
(TCEP) 
B Bastiaensen et al. (2018), Chen et al. (2018), Fromme et al. (2014), He et al. 
(2018), Ospina et al. (2018), Sun et al. (2018), Van den Eede et al. (2013) 
Bis(chloroisopropyl) phosphate (BCIPP) Tri(chloroiso-propyl) 
phosphate (TCIPP) a 
B Bastiaensen et al. (2018), Carignan et al. (2017), Chen et al. (2018), Fromme et al. 






B Bastiaensen et al. (2018), Carignan et al. (2017), Chen et al. (2018), He et al. 
(2018), Ospina et al. (2018), Sun et al. (2018), Van den Eede et al. (2013) 
Diphenyl phosphate (DPHP) b Triphenyl phosphate (TPHP) B 
Biscresyl phosphate (BMPP) Tricresyl phosphate (TMPP) B Chen et al. (2018), Fromme et al. (2014), He et al. (2018), Ospina et al. (2018), 
Sun et al. (2018) 
Bis(2-butoxyethyl) phosphate (BBOEP) Tris(2-butoxyethyl) phosphate 
(TBOEP) a 
B Bastiaensen et al. (2018), Chen et al. (2018), Fromme et al. (2014), He et al. 
(2018), Sun et al. (2018), Van den Eede et al. (2013) 
Diethyl phosphate (DEP) Triethyl phosphate (TEP) B Sun et al. (2018) 
Di-n-butyl phosphate (DNBP) Tri-n-butyl phosphate (TNBP) B Bastiaensen et al. (2018), Chen et al. (2018), Fromme et al. (2014), He et al. 
(2018), Ospina et al. (2018), Sun et al. (2018), Van den Eede et al. (2013) 
Bis(2-ethylhexyl) phosphate (BEHP) Tris(2-ethylhexyl) phosphate 
(TEHP) 
B He et al. (2018), Sun et al. (2018) 
Mono-substituted isopropylphenyl phenyl 
phosphate (i,p-PPP) 
Isopropyl triphenyl phosphate 
(i,p-TPP) 
C Carignan et al. (2017), Phillips et al. (2018) 
a Additional biomarkers exist for this parent compound, see text for details. 
b Unspecific biomarker, see text for details.  
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urine minimizes the contamination risks and is therefore the preferred 
approach, besides the obvious disadvantage of the invasive sampling of 
serum (Table 10). Half-lives of PAH metabolites in urine were given 
with a range of 5 hours to 17 days (Esteban and Castaño, 2009). 
While HPLC in combination with fluorescence detection is still ap-
plied in the analysis of PAH metabolites (Yamamoto et al., 2015), the 
current method of choice providing highest sensitivity and selectivity is 
LC-MS/MS with electrospray ionisation in negative mode (Table 10). 
Based on sample intakes of 3–10 mL, MDLs of 1–50 pg/mL were 
achieved (Lankova et al., 2016; Onyemauwa et al., 2009; Xu et al., 
2004). GC-based methods can offer comparable sensitivity, but require 
an additional derivatization step (Li et al., 2014). 
The urine samples are first subjected to enzymatic conjugate clea-
vage, for example using β-glucuronidase/arylsulfatase (Lankova et al., 
2016). Both serum and urine samples can then be further processed by 
common extraction techniques, e.g. solid-phase extraction, and clean- 
up steps (Jacob and Seidel, 2002). Labelled standards are commercially 
available for many parent PAHs and their metabolites. Certified re-
ference materials are available for PAH metabolites in urine (Schantz 
et al., 2015). 
4.3.8. Arylamines 
The major metabolites of arylamines are aminophenols and N- 
acetylated aminophenols excreted as conjugates (glucuronides and 
sulfates) or free compounds in urine. Extraction with organic solvents 
without enzymatic or acid pre-treatment at neutral pH yields free ar-
ylamines, aminophenols, N-acetylated arylamines and N-acetylated 
aminophenols since the conjugates are too polar to be extractable in 
sufficient amounts under these conditions. Enzymatic treatment of 
urine cleaves glucuronides and sulfates, yielding arylamines, N-acety-
lated arylamines and aminophenols. Boiling of urine in base or acid 
yields the parent arylamines and aminophenols (Sabbioni, 2017). 
The biomarkers included in Table 11 reflect the multiple potential 
exposure sources that exist for arylamines. MDA, MOCA, 2,4-TDA and 
2,6-TDA mainly reflect the exposure to plastic products. 4-Chloroani-
line (CA) and 3,4-dichloroaniline (DCA) are metabolically released 
from pesticides. Aniline, 4-ABP, 2-NA, 2-MA, 4-MA and 2-MeOA appear 
to be ubiquitously present in the environment according to former 
biomonitoring studies (Sabbioni, 2017) and are thus markers to 
monitor the general exposure to arylamines. The aniline biomarker N- 
acetyl-4-aminophenol included in Table 11 can also result from Para-
cetamol intake and does thus not meet the criteria in Table 2 as it is no 
specific biomarker for aniline (or Paracetamol) (Dierkes et al., 2014). 
N-Hydroxyarylamines are toxic intermediates of arylamines and 
nitroarenes and can form adducts with hemoglobin (Hb-adducts), al-
bumin, proteins and DNA in a dose-dependent manner (Sabbioni and 
Jones, 2002). Most of the arylamine Hb-adducts can be cleaved in vitro, 
by mild acid or base, to release the arylamines. Hb-adducts are a marker 
of the biological availability of the toxic N-hydroxyarylamine and have 
been analyzed in biomonitoring studies (Bryant et al., 1988; Sabbioni, 
2017). 
While the biomonitoring of urinary metabolites (Table 11) is a less 
invasive process than blood monitoring, it only represents recent ex-
posure to arylamines, i.e. of the past 24–48 h (Sabbioni, 2017). For 2,5- 
TDA, for example, a half-life of 8 h was reported (Gube et al., 2011). In 
case of intermittent exposure, urinary metabolites may not be detected 
and subjects may be misclassified as non-exposed. In addition, the 
quantification of arylamines in urine, which can originate from several 
products, does not give information about the biologically active N- 
hydroxyarylamine. Measuring the parent arylamine in urine does not 
indicate how much of the toxic intermediate is bioavailable since the 
yields of N-hydroxyarylamines resulting from different derivatives are 
unknown. Thus, Hb-adduct values have the potential to be a better 
exposure marker for the risk assessment of arylamines than urinary 
levels of metabolites. 
The analysis of Hb-adducts has shown better agreement between 
laboratories than the analysis of urinary metabolites, probably related 
to differences in hydrolysis conditions (Sabbioni, 2017). Therefore, in 
order to improve comparability, the methods for urinary analyses might 
have to be standardized to a greater extent. Regarding the instrumental 
analysis, the most sensitive methods include the derivatization of the 
amino group with perfluorinated anhydride and analysis by GC–MS 
(ECNI). LC-MS/MS and GC–MS/MS (EI) have been used as well, with 
high sensitivity and large sample throughputs (Bhandari et al., 2016; 
Mazumder et al., 2019). Based on sample intakes of 0.2–5 mL, MDLs of 
2–1000 pg/mL could be achieved (Table 11). As with other widely used 
chemicals, external contaminations risks have to be considered in the 
sampling and processing strategies. 
4.3.9. Cadmium and chromium 
Cadmium has been included in many human biomonitoring studies. 
It is preferably monitored in whole blood or urine (Table 12), with 
urinary Cd reflecting cumulative exposure and accumulation in the 
kidney, while the Cd concentration in blood also reflects more recent 
exposure (Jarrett et al., 2008; Vacchi-Suzzi et al., 2016; Wiseman et al., 
2017). Chromium analyses in urine are common, but possess a number 
of disadvantages, such as a short half-life (Paustenbach et al., 1997), 
conflicting with the criteria in Table 2. 
Erythrocytes are the current matrix of choice to quantify Cr (VI) 
exposure, since Cr (VI), mainly as chromate CrO42-, can cross the cell 
membrane through active anion channels, whereas Cr (III) is unable to 
cross membranes (Goldoni et al., 2010; Devoy et al., 2016). Thus, al-
though total Cr is determined in erythrocytes, it is assumed to only 
reflect Cr (VI). Targeting occupational exposure to Cr (VI), exhaled 
breath condensate has also been used, with selective determination of 
Cr (VI) (Goldoni et al., 2006; Leese et al., 2017). 
Table 10 
Prioritized biomarkers for polycyclic aromatic hydrocarbons (PAHs). Categories A and B apply to sufficient and insufficient data availability, respectively, of a certain 
biomarker in human biomonitoring. Matrix and analytical method of choice were urine and high performance liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), respectively, for all PAH biomarkers.      
Biomarker Parent compound Category Reference  
1-Hydroxypyrene Pyrene A Barbeau et al. (2014), Fan et al. (2012), Jacob III et al. (2007), Lankova et al. (2016), Onyemauwa et al. (2009), 
Xu et al. (2004) 
Hydroxynapthalenes a Naphthalene A Fan et al. (2012), Jacob III et al. (2007), Lankova et al. (2016), Onyemauwa et al. (2009), Xu et al. (2004) 
Hydroxyfluorenes b Fluorene A 
Hydroxyphenanthrenes c Phenanthrene A Fan et al. (2012), Jacob III et al. (2007), Onyemauwa et al. (2009) 
Hydroxychrysenes d Chrysene B Onyemauwa et al. (2009), Xu et al. (2004) 
3-Hydroxybenzo[a]-pyrene Benzo[a]pyrene A Barbeau et al. (2014), Lankova et al. (2016), Onyemauwa et al. (2009), Xu et al. (2004) 
1-Hydroxybenz[a]-anthracene Benz[a]-anthracene B Onyemauwa et al. (2009), Xu et al. (2004) 
a 1- and 2-Hydroxynaphthalene 
b 2-, 3- or 9-Hydroxyfluorene 
c 1-, 2-, 3-, 4- or 9-Hydroxyphenanthrene 
d 1-, 3- or 6-Hydroxychrysene  
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Inductively coupled plasma (ICP)-MS is state-of-the-art in-
strumentation to reach the detection limits required in human biomo-
nitoring. MDLs for Cd in blood and urine are typically 10–100 pg/mL 
(Aoki et al., 2017; Bonberg et al., 2017; Ciesielski et al., 2012; Garner 
and Levallois, 2017). For Cr in erythrocytes, MDLs of 10–250 pg/mL 
have been reported (Goldoni et al., 2010; Heitland et al., 2017). For 
trace level quantification of Cd in urine via ICP-MS, special precautions 
apply: Interferences from molybdenum oxides and molybdenum hy-
droxide need to be eliminated (Jarrett et al., 2008) and other inter-
ferences from tin (114Sn) have to be corrected for. The Mo interferences 
could be overcome by ICP-dynamic reaction cell (DRC)-MS, a single- 
element technique which can be combined with the multi-element ICP- 
MS analysis (Jarrett et al., 2008; Cañas et al., 2013). The Mo-induced 
bias was not observed in blood analyses, presumably due to lower Mo 
levels in blood (Jarrett et al., 2008). Speciation of Cr can be achieved if 
ICP-MS is preceded by HPLC (Séby et al., 2003). 
The sample preparation for Cd can consist of a simple acid or al-
kaline dilution of urine or blood (Bonberg et al., 2017; Jarrett et al., 
2008). Microwave digestion with HNO3 and/or H2O2 is an alternative, 
following dilution of the sample, especially for frozen blood, which may 
contain micro clots (Henríquez-Hernández et al., 2017). Quantification 
should be based on isotope dilution (Heumann, 2004). It must be borne 
in mind that the results in urine should be adjusted for creatinine 
(Garner and Levallois, 2017; Middleton et al., 2016). For Cr, ery-
throcyte samples are diluted with acid and heated prior to ICP-MS 
analysis (Goldoni et al., 2010). In order to avoid contamination, it is 
important to use metal-free tubes for sample collection and to be aware 
of stainless steel needles as potential contamination sources. 
4.4. Need for developments 
Biomonitoring of the general population requires analytical 
methods of high selectivity and high sensitivity, due to low con-
centrations and limited sample volumes. The most common matrices 
are urine and blood (serum), and for the latter in particular increases in 
sensitivity cannot always be achieved by increases in sample amount. 
Triple quadrupole MS techniques have increased sensitivity in many 
fields of human biomonitoring, and further developments towards 
lower MDLs can be expected within analytical chemistry. 
The quest for lower MDLs should be accompanied by an increased 
awareness of contamination issues or other interferences in the che-
mical analyses. These issues should find reflection in the pre-analytical 
and the analytical phase of human biomonitoring studies. Some bio-
markers are more prone to external contamination than others, i.e. 
parent compounds widely distributed in products and the environment 
(e.g. flame retardants, PFASs) as opposed to specific metabolites formed 
in human metabolism. A better understanding of toxicokinetics and 
metabolism might provide novel and more robust biomarkers of ex-
posure. 
The collection of blood requires invasive sampling, which is difficult 
for sensitive populations such as children, and always accompanied by 
volume limitations. Non-invasive matrices such as hair, nails and saliva 
show promising results in terms of detectable concentrations, and might 
offer additional advantages regarding stability during transport and 
storage (Table 2). However, the interpretation of these results can be 
ambiguous and needs further research, for example related to internal 
exposure, individual variability, contamination and other parameters 
Table 11 
Prioritized biomarkers and analytical methods for arylamines. The categories A, B and C apply to sufficient, insufficient and limited data availability, respectively, of 
a certain biomarker in human biomonitoring. Urine was the matrix of choice for all biomarkers. LC-MS/MS: High performance liquid chromatography-tandem mass 
spectrometry. GC–MS (ECNI/EI): Gas chromatography-mass spectrometry with electron capture negative ionization / electron impact ionization.       
Biomarker Parent compound a Category Instrumental analysis Reference  
4,4-Methylenedianiline (MDA) A LC-MS/MS; GC–MS (ECNI) Bhandari et al. (2016), Cocker et al. (2017), Lépine et al. (2019) 
4,4-Methylenebis(2-chloroaniline) (MOCA) A LC-MS/MSb Marand et al. (2004), Shih et al. (2007) 
2,4-Toluoenediamine (2,4-TDA) B LC-MS/MS; GC–MS (ECNI) Bhandari et al. (2016), Cocker et al. (2017), Lépine et al. (2020), Marand 
et al. (2004) 2,6-Toluenediamine (2,6-TDA) B LC-MS/MS; GC–MS (ECNI) 
2,5-Toluenediamine (2,5-TDA) B GC–MS c, d Gube et al. (2011) 
1,4-Phenylenediamine (1,4-PDA) B LC-MS/MS; GC–MS d Bhandari et al. (2016), Gube et al. (2011) 
4-Aminobiphenyl (4-ABP) B LC-MS/MS; GC–MS (ECNI); GC–MS/MS 
(EI) 
Mazumder et al. (2019), Riedel et al. (2006), Weiss and Angerer (2002), 
Yu et al. (2014) 
2-Naphthylamine (2-NA) B LC-MS/MS; GC–MS (ECNI); GC–MS/MS 
(EI) 
2-Methylaniline (2-MA) B GC–MS (ECNI); GC–MS (EI); GC–MS/MS 
(EI) 
Mazumder et al. (2019), Riedel et al. (2006), Weiss and Angerer (2002) 
4-Methylaniline (4-MA) C GC–MS (EI); GC–MS/MS (EI) Mazumder et al. (2019), Weiss and Angerer (2002) 
2-Methoxyaniline (2-MeOA) C GC–MS (EI); GC–MS/MS (EI) 
4-Chloroaniline (4-CA) C GC–MS (EI) Weiss and Angerer (2002) 
3,4-Dichloroaniline (3,4-DCA) C GC–MS (EI) 
Acetanilide Aniline B LC-MS/MS Dierkes et al. (2014) 
N-Acetyl-4-aminophenol Aniline B LC-MS/MS 
a Also biomarkers for diisocyanates. 
b GC–MS primarily used in older studies, e.g. Vaughan and Kenyon (1996). 
c Analysis by LC-MS/MS likely possibly, by analogy to 2,4-TDA and 2,6-TDA. 
d Ionization technique not specified.  
Table 12 
Prioritized biomarkers, human matrices and analytical methods for cadmium and chromium. The categories A and B apply to sufficient and insufficient data 
availability, respectively, of a certain biomarker in human biomonitoring. ICP-MS: Inductively coupled plasma-mass spectrometry.       
Biomarker Matrix Category Instrumental analysis Reference  
Cd Blood A ICP-MS Aoki et al. (2017), Bonberg et al. (2017), González-Atuña et al. (2017), Wiseman et al. (2017) 
Cd Urine A ICP-MS a Ciesielski et al. (2012), Garner and Levallois (2017), Jarrett et al. (2008), Middleton et al. (2016) 
Cr b Erythrocytes (red blood cells) B ICP-MS c Devoy et al. (2016), Goldoni et al. (2010), Heitland et al. (2017) 
a Dynamic reaction cell (DRC)-ICP-MS can overcome the interferences with molybdenum. 
b As a measure of Cr (VI) exposure as only Cr (VI) can cross the cell membrane. 
c The study by Devoy et al. (2016) used Atomic Absorption Spectroscopy (AAS).  
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listed in Table 2 and Table 3. The technical ability to analyse a chemical 
in a human matrix alone does not guarantee a suitable EB/M combi-
nation. 
For substances in Category B, some EB/M combinations and ana-
lytical methods have been published, but are not widely or routinely 
used. Further work in HBM4EU and other initiatives, with an integrated 
focus on QA/QC, will likely lead to a broader dissemination and use of 
these methods while keeping a critical approach to analytical quality. 
Compounds of the C category require more research, and this category 
is continuously extended in HBM4EU as new chemicals are placed on 
the market or knowledge of new exposure issues and situations in-
creases. This includes, for example, short-chain PFSAs and PFCAs, 
which bioaccumulate to a lesser extent than the longer-chain PFASs, but 
might have other toxicokinetics. No analytical method was specified for 
the metabolites of the Category C phthalates (DIPeP, DnHxP) and 
method development is needed, especially as these phthalates are 
classified as SVHCs on account of their reproductive toxicity. 
Experiences in HBM4EU with the development of analytical methods 
for less-studied compounds and preparations towards their routine 
analyses will also be relevant for other biomonitoring programmes, e.g. 
NHANES and CHMS, and vice versa. 
For the HFRs, no category A compounds were identified beyond 
PBDEs, HBCDD and TBBPA, implying need for further research on other 
current-use compounds. For OPFRs, discussion of most suitable bio-
markers should continue, as little knowledge is available on the main 
stable (and oxidative) metabolites. PAH biomonitoring is established 
well, but does not involve alkylated and heterocyclic PAHs on a routine 
basis, which also leaves room for developments within HBM4EU and 
other biomonitoring programmes. 
For arylamines, the EB/M requirement for specificity is only ful-
filled in an occupational environment. The general population can be 
exposed to several products with the same urinary biomarkers. 
Therefore, possible health effects should be related to the biologically 
active metabolite, the N-hydroxyarylamine, which are measured as Hb- 
adducts. The determination of Hb-adducts requires more time than the 
analysis of urine, but is established in e.g. NHANES and CHMS. 
In general, the extension from initiatives focusing on method de-
velopment to a large-scale human biomonitoring study such as 
HBM4EU is substantial and challenging. It includes aspects of capacity 
building in terms of a wider geographical coverage of analyses of 
Category A compounds as well as work towards the establishment of 
analyses of Category B and C compounds, all accompanied by QA/QC 
programmes. The objective of high-quality and comparable human 
biomonitoring data across Europe is ambitious, but necessary to be able 
to detect agreements and differences in sub-groups of the European 
population. 
5. Conclusions 
The project HBM4EU has prioritized a first set of seven substance 
groups and two metals of relevance for human health. With the long- 
term objective of harmonized and quality-assured biomonitoring, this 
study addressed the most suitable biomarkers, human matrices and 
analytical methods for the priority substance groups and metals. It at-
tempted an objective approach of defining criteria for suitable bio-
marker/matrix combinations as well as analytical methods and ap-
plying these to the currently available scientific literature. The 
evaluation resulted in a list of recommended parent compounds, me-
tabolites and metal (species), each in a preferred human matrix, and 
state-of-the art methodology for their determination, with a focus on 
sensitivity. However, it also became obvious that the consistent appli-
cation of the criteria was compromised in some cases. For example, 
some common biomarkers can be metabolites of several parent com-
pounds and thus do not reflect exogenous exposure in a quantitative 
way. In addition, the maturity of analytical methods varied con-
siderably among and within the priority substances and metals, with 
nearly each compound group including a number of Category C com-
pounds with limited data availability. Thus, the study also revealed 
multiple needs for development, mainly in terms of higher sensitivity, 
non-invasive sampling and more stringent QA/QC. Research activities 
in these fields are ongoing and show promising results, which, however, 
do not yet possess the maturity for large-scale biomonitoring applica-
tions. These developments should be followed closely. They will likely 
also be relevant for other biomonitoring programmes outside of Europe. 
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